Having a large clinical trial portfolio means giving patients treatment options often not available anywhere else, and years before they become the standard of care. To learn more about Karmanos Cancer Institute clinical trials or to see if a trial is right for you, please call 1-800-KARMANOS (1-800-527-6266) or request an appointment below
  • A Phase 1, Open-Label, Dose Escalation and Expansion Study of ASP1012, an Oncolytic Virus, in Participants with Locally Advanced or Metastatic Solid Tumors

    Cancer Categories
    • Gastrointestinal (GI),Gynecologic,Skin
    Karmanos Trial ID
    • 2023-093
    NCT ID
    • NCT06171178
    Age Group
    • Adult
    • National
    PhaseClick for Clinical Trial Phase DefinitionPhase I
    Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
    • Phase I
    Principal Investigator


    Primary Objectives:

    • To determine the safety and tolerability of ASP1012 (±pembrolizumab) in participants with locally advanced or metastatic solid tumors
    • To determine the MTD and/or candidate RP2D of ASP1012

    Secondary Objectives:

    • To evaluate the PK and virus shedding of ASP1012
    • To evaluate the ADAs of ASP1012
    • To evaluate anti-tumor effects of ASP1012
    • To evaluate tumor-specific virus delivery
    • To evaluate tumor biomarker changes related to ASP1012 treatment (CRC and ovarian)
  • Locations


    Karmanos Cancer Institute - Detroit Headquarters

    4100 John R
    Detroit, MI 48201
    Get Directions
    Phone: 800-527-6266

    Karmanos Cancer Institute at Weisberg Cancer Center - Farmington Hills

    31995 Northwestern Hwy
    Farmington Hills, MI 48334
    Get Directions
    Phone: 800-527-6266